Poster Abstract Session:
56. Fungal Disease: Management and Outcomes
Thursday, October 4, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall

Tracks: Adult ID, Epidemiology and Infection Control, HIV-STD-TB, Investigative ID, Pediatric ID, Trainee


Presentations:
354
Evidence of aspergillosis among patients with influenza-associated hospitalizations — United States, 2005–2017
Mitsuru Toda, PhD; Karlyn Beer, PhD; Alissa O'Halloran, MSPH; Arthur Reingold, MD, FIDSA; Nisha Alden, MPH; Kimberly Yousey-Hindes, MPH, CPH; Evan J. Anderson, MD; Susan Bohm, MS; Melissa McMahon, MPH; Lisa Butler, MPH; Eva Pradhan, MPH, MHA; Christina B. Felsen, MPH; Laurie Billing, MPH; Ann Thomas, MD, MPH; H. Keipp Talbot, MD, MPH; Gregg M. Reed, MPH; Tom Chiller, MD, MPH; Shikha Garg, MD, MPH; Brendan R. Jackson, MD, MPH
355
Invasive pulmonary aspergillosis (IPA) complicating respiratory viral infections in patients with hematological malignancies
Eleni Magira, MD PhD; Roy F. Chemaly, MD, MPH, FIDSA, FACP; Ying Jiang, MS; Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FACP, FIDSA, FECMM, FAAM
356
Bronchoalveolar lavage fluid cytology by GMS stain for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies: analysis of 67 episodes.
Ana Fernández-Cruz, M.D., Ph.D.; Eleni Magira, M.D., Ph.D.; Sang Taek Heo, M.D. PhD.; Scott Evans, MD; Jeffrey Tarrand, MD; Dimitrios P Kontoyiannis, MD, ScD, PhD
Posters
  • IDWEEK 2018 Cytology BAL.pdf (189.9 kB)
  • 357
    Aspergillus isolates remain largely susceptible to azoles and other antifungals at a large transplant program using azole prophylaxis
    Eileen Driscoll, BS; Cornelius J. Clancy, M.D.; Kevin Squires, BS; Ryan K. Shields, PharmD; Minh-Hong Nguyen, MD
    358
    Comparison of Voriconazole (VORI), Isavuconazole (ISAV) and Posaconazole (POSA) in the initial treatment of patients with invasive aspergillosis (IA)
    Matthew P. Cheng, MD; José Luis Orejas, MD; Esther Arbona-Haddad, MD; Francisco M Marty, MD; Sophia Koo, MD, FIDSA; Sarah Hammond, MD
    359
    Baseline serum Aspergillus galactomannan index among Aspergillus species in hematologic malignancies patients with invasive pulmonary aspergillosis
    Eleni Magira, MD PhD; Ying Jiang, MS; Sang Taek Heo, M.D. PhD.; Jeffrey Tarrand, MD; Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FACP, FIDSA, FECMM, FAAM
    361
    Changing epidemiology of Blastomyces dermatitidis infection in Quebec, Canada: A Retrospective Multicenter Study
    Kevin Dufour, MD; Andrée Ann Pelletier, MD; Mélina Denis, BSc; Nicolas Gagnon, Pharmacy student; Philippe Dufresne, PhD, MSc, Mcb A, RMCCM; Claire Nour Abou Chakra, PhD; Alex Carignan, MD, MSc, FRCPC
    Posters
  • Poster Blasto_v3.pdf (610.4 kB)
  • 362
    Species Distribution and Trends of Invasive Candidiasis in the United States, 2009-2015, Using a Large Electronic Medical Record Database
    Emily Ricotta, PhD, ScM; Yi Ling Lai, MPH; Sameer S. Kadri, MD, MS; Michail Lionakis, M.D., Sc.D.; D. Rebecca Prevots, PhD, MPH; Jennifer Adjemian, PhD
    363
    National Burden of Candidemia, United States, 2017
    Sharon Tsay, MD; Sabrina Williams, MPH; Yi Mu, PhD; Erin Epson, MD; Helen Johnston, MPH; Monica M. Farley, MD, FIDSA; Lee H. Harrison, MD; Brittany Vonbank, MPH; Sarah Shrum, MPH; Ghinwa Dumyati, MD, FSHEA; Alexia Zhang, MPH; William Schaffner, MD, FIDSA, FSHEA; Shelley Magill, MD, PhD; Snigdha Vallabhaneni, MD, MPH
    364
    The Capital District of New York State, Likely a New Blastomycosis Endemic Region
    Robert McDonald, MD, MPH; Elizabeth M. Dufort, MD; Ellis Tobin, MD, FIDSA; Brendan R. Jackson, MD, MPH; Alexandra Newman, DVM, MPH; Debra S. Blog, MD, MPH
    365
    Posters
  • 365_IDWPOSTER.pdf (386.4 kB)
  • 366
    Impact of Obesity in Patients with Candida Bloodstream Infections
    Katie E. Barber, PharmD; Jamie L. Wagner, PharmD; Jennifer Miller, PharmD Candidate; Emily Lewis, PharmD Candidate; Kayla R. Stover, PharmD, BCPS
    367
    Influence of Body Weight and Outcomes in Candidemia
    Mary Musgrove, PharmD; Rachel M Kenney, PharmD; Susan Davis, PharmD; Jose Vazquez, MD, FACP, FIDSA
    368
    COMMUNITY-ONSET CANDIDEMIA: TRENDS OVER SEVEN YEARS
    Rebecca Witherell, MD; Babak Hooshmand, MD; Kathleen Riederer, MT; Leonard Johnson, MD; Riad Khatib, MD
    369
    Using Hybrid Models and Blockchain technology as a Means to Develop a Novel Propensity Score for Candidemia and Invasive Candidiasis
    Arni Sr Srinivasa Rao, PhD; Jose Vazquez, MD, FACP, FIDSA; Luis Ostrosky-Zeichner, MD, FIDSA, FSHEA
    370
    Efficacy of cochleated amphotericin B (C-AMB) in mouse models of oropharyngeal and vulvovaginal candidiasis
    Jigar V. Desai, PhD; Ruying Lu, BS; Alexandra F. Freeman, MD; Edmund Tramont, MD, FIDSA; Jerry Jabbour, PhD; Raphael J. Mannino, PhD; Michail S. Lionakis, MD, ScD
    Posters
  • 2018_IDWeek_Poster_CAMB.pdf (1.8 MB)
  • 371
    Risk Factors for Non-Albicans Candidal Vulvovaginitis
    Andrea Boyd Tressler, PhD; Chelsea Fortin, MD; Milena Radeva, MS; Oluwatosin Goje, M.D., MSCR
    372
    Attributable Mortality of Candidemia after Introduction of Echinocandins
    Florian Cornely, Medical Student; Oliver Cornely, MD, FACP, FIDSA, FAAM; Philipp Koehler, MD; Felix Koehler, Medical Student; Sibylle Mellinghoff, MD
    Posters
  • Poster IDWEEK 2018.pdf (576.6 kB)
  • 373
    Impact of Concurrent Renal Replacement Therapy on Treatment Outcomes of Candidemia in Adults
    Brandon Hill, PharmD, BCPS; Dustin Wilson, PharmD, BCPS; Richard Drew, PharmD, MS, FCCP, FIDP
    Posters
  • CandidemiaRRT_IDWeek_9.20.pdf (273.7 kB)
  • 376
    Predictive Model for Fluconazole Resistance in Patient with Candida Bloodstream Infection
    Abdullah Aljorayid, MD; Ryan Kronen, B.A.; Ana S. Salazar, MD; Kevin Hsueh, MD; Charlotte Lin, MD; William Powderly, MD; Andrej Spec, MD
    Posters
  • ID week18-Fluc R 2.pdf (318.8 kB)
  • 378
    Candida auris fungemia: Risk factors and outcome
    Rodney Adam, M.D., FIDSA; Nancy Okinda, MMED; Gunturu Revathi, Clinical Microbiologist; Melanie Fontaine, M.Sc.; Elizabeth Kagotho, MMED; Mariana Castanheira, PhD; Michael A. Pfaller, M.D.; Daniel Maina, MMED
    379
    Pediatric Bloodstream Infections by Candida auris in Colombia: Clinical Characteristics and Outcomes of 34 cases
    Indira Berrio, MD, MSc; Diego H Caceres, MSc; Wilfrido Coronell R, MD, PhD; Soraya Salcedo, MD, MSc; Laura Mora, MD; Adriana Marin, MSc; Carmen Varón, .; Patricia Escandón, MSc; Sandra Rivera, .; Tom Chiller, MD, MPH; Snigdha Vallabhaneni, MD, MPH
    380
    Drosophila melanogaster as a Facile Model for Large-Scale Studies of Virulence Mechanisms and Antifungal Drug Efficacy in Candida auris Candidiasis
    Ashwini Bandi, ---; Sebastian Wurster, MD; Nitya M Raman, PhD; Nathaniel Albert, MS; Issam I Raad, MD, FACP, FIDSA, FSHEA; Nicholas Beyda, PharmD, BCPS; Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FACP, FIDSA, FECMM, FAAM
    381
    Morphologic Changes Associated with Echinocandin Tolerance Enhance Immunoevasion of C. glabrata (Cg)
    Chenlin Hu, PhD; Dimitrios P Kontoyiannis, MD, ScD, PhD; Nicholas D. Beyda, PharmD, BCPS
    383
    An Increased Rate of Candida parapsilosis Infective Endocarditis is Associated with Injection Drug Use
    J. Alexander Viehman, MD; Cornelius J. Clancy, M.D.; Guojun Liu, BS; Shaoji Cheng, MD, Ph.D; Louise-Marie Oleksiuk, PharmD; Ryan K. Shields, PharmD; Minh-Hong Nguyen, MD
    384
    Findings From a Candida auris Admission Screening Pilot in New York State
    Elizabeth M. Dufort, MD; Richard Erazo, BS; Monica Quinn, RN, MS; Sudha Chaturvedi, PhD; Snigdha Vallabhaneni, MD, MPH; Valerie B. Haley, PhD; Emily Lutterloh, MD, MPH; Jiankun Kuang, M.S.; Carolyn Stover, B.A.; Coralie Bucher, MPH; Robert McDonald, MD, MPH; Eleanor H. Adams, MD, MPH; Debra S. Blog, MD, MPH
    385
    The Value Added from Candida auris Point Prevalence and Environmental Studies in New York State
    Eleanor H. Adams, MD, MPH; Monica Quinn, RN, MS, CIC; Belinda Ostrowsky, MD, MPH; Karen Southwick, MD; Jane Greenko, RN, MPH, CIC; Rafael Fernandez, MPH; Rutvik Patel, MSW; Ronald Jean Denis, BS; Richard Erazo, BS; Sudha Chaturvedi, PhD; Lynn Leach, MS; Yan Chun Zhu, MS; Valerie B. Haley, PhD; Sharon Tsay, MD; Snigdha Vallabhaneni, MD, MPH; Emily C. Lutterloh, MD, MPH; Debra S. Blog, MD, MPH; Elizabeth M. Dufort, MD
    386
    A Reexamination of Disseminated Coccidioidomycosis: The Natural History in the Pre-Antifungal Era
    Derek Bays, MD; George R. Thompson, MD; Susan Reef, MD; Linda Snyder, MD; Alana Freifeld, BS; Machelle Wilson, PhD; John Galgiani, MD
    387
    Coccidioidomycosis In Children Younger Than Two Years Of Age: A Retrospective Review
    Rebecca Filbrandt, MD; Fouzia Naeem, MD, MS; Chokechai Rongkavilit, MD; Mohammad Nael Mhaissen, MD
    388
    New Observations in Coccidioidomycosis Serology
    Ian Mchardy, PhD; Bao-Tran Dinh, BS; Derek Bays, MD; Sarah Waldman, MD; Ethan Stewart, DO; Demosthenes Pappagianis, MD, PhD, FIDSA; George R. Thompson, MD
    Posters
  • IDSA - 2018 - Titer Trends.pdf (602.9 kB)
  • 389
    Pediatric Musculoskeletal Coccidioidomycosis In Central California: Single Center Experience.
    Daniel Merriott, MD; Joseph Gerardi, DO; Purushottam Gholve, MD; Fouzia Naeem, MD, MS
    391
    Evaluation of 2nd Generation Triazoles in the Treatment of Refractory Coccidioidomycosis
    Janet Yoon, Pharm.D.; Jeff Jolliff, Pharm.D., BCPS, AAHIVP; Brittany Andruszko, Pharm.D.; Arash Heidari, M.D.; Royce Johnson, M.D.
    Posters
  • Poster391_IDWeek_Final.pdf (490.5 kB)
  • 393
    Isavuconazole in the Treatment of Coccidioidal Meningitis
    Arash Heidari, M.D.; Miriam Quinlan, MD; David Benjamin, MD; Ian Mchardy, PhD; Stuart H. Cohen, MD, FIDSA, FSHEA, FACP; Royce H. Johnson, M.D., F.A.C.P., FIDSA; George R. Thompson, MD
    394
    Outcomes in Patients with Disseminated Non-Central Nervous System Cryptococcus
    Carlos Mejia, MD; Krunal Raval, MD; William Powderly, MD; Andrej Spec, MD
    395
    Missed Opportunities for Diagnosis of Cryptococcal Disease in Patients from Florida
    Ana S. Salazar, MD, MPHS; Matt Keller, MS; Margaret A. Olsen, PhD, MPH; William Powderly, MD; Andrej Spec, MD
    Posters
  • Salazar_IDWEEK_4.pdf (1.7 MB)
  • 396
    Clinical Features of Proven and Probable Cases of Histoplasmosis and the Role of Urinary Histoplasma Antigen Testing: A Case Series from India
    Nitin Bansal, MD internal Medicine; Nandini Sethuraman, MD; Madhumitha R, MD FNB; P Senthur Nambi, FNB ID; Suresh Kumar D, MD FNB; V Ramasubramanian, MD, MRCP; Ram Gopalakrishnan, MD, MRCP, AB (Internal Medicine), AB (Infectious Diseases), FIDSA
    Posters
  • Urine histo poster(1).pdf (161.0 kB)
  • 397
    Long-term Mortality of HIV Patients Following Cryptococcal Infection
    Matthew Hevey, MD; Krunal Raval, MD; Rachel Presti, MD, PhD; William Powderly, MD; Andrej Spec, MD
    Posters
  • IDweekPosterV6.pdf (858.5 kB)
  • 399
    Multi-centre observational study on epidemiology, treatment and outcome of Mucormycosis in India
    Atul Patel, MD, FIDSA; Harsimran Kaur, MD; Immaculata Xess, MD; Joy S Michael, MD, FRC(Path); Jayanthi Savio, MD; Shivaprakash Rudramurthy, MD; Rakesh Singh, MD; Prakash Shastri, MD; Pamidimukkala Umabala, MD; Raman Sardana, MD; Anupama Jyoti Kindo, MD; Malini Capoor, MD; Sangeetha Mohan, MD; Arunaloke Chakrabarti, MD, FIDSA
    Posters
  • FISF Mucor study Poster.pdf (3.1 MB)
  • 400
    The Frequency and Clinical Characteristics of Positive Galactomannan Assay Results in Patients with Mucormycosis
    Sungim Choi, M.D; Joon Seon Song, M.D; Ji Hyun Yun, MD; Jung Wan Park, MD; Kyung Hwa Jung, MD; Kyeong Min Jo, M.D; Jiwon Jung, MD; Min Jae Kim, MD; Yong Pil Chong, MD, PhD; Young Soo Park, M.D; Sang-Oh Lee, MD, PhD; Sang-Ho Choi, MD, PhD; Jun Hee Woo, M.D; Yang Soo Kim, MD, PhD; Sung-Han Kim, MD, PhD
    401
    Pneumocystis jirovecii pneumonia in renal transplant recipients after a 6-month trimethoprim-sulfamethoxazole prophylaxis: a case-control study
    Se Yoon Park, MD; Sung Shin, MD; Young-Hoon Kim, MD; Joo Hee Jung, RN; Sung-Han Kim, MD, PhD; Duck Jong Han, MD, PhD
    402
    Breakthrough Pneumocystis jirovecii Pneumonia among Cancer Patients: Opportunity for Antimicrobial Stewardship?
    Steven Roncaioli, MPH; Andrew Bryan, MD, PhD; Erica Stohs, MD, MPH; Catherine Liu, MD, FIDSA; Ania Sweet, PharmD; Steven Pergam, MD, MPH, FIDSA
    Posters
  • PJP_IDWeek_Poster2018_PDF.pdf (187.2 kB)
  • 403
    Prognostic factors in 260 adults with invasive scedosporiosis from literature and FungiScope™
    Danila Seidel, PhD; Arne Meißner, MD; Michaela Lackner, PHD; Ellen Piepenbrock, MD; Jon Salmanton García, MSc; Sibylle Mellinghoff, MD; Axel Hamprecht, MD; Janne Vehreschild, Prof. Dr. med.; Maria J. G. T. Vehreschild, MD; Hilmar Wisplinghoff, MD; Oliver A. Cornely, MD
    404
    Tinea Capitis: Are Epidemiologic Shifts Associated With Distinct Clinical Presentations?
    Sigrid Collier, M.D.; Cuong Nguyen, MD; Ashley Marten, MD; Sheilagh Maguiness, MD; Kristen Hook, MD
    Posters
  • IDSA.pdf (1.4 MB)
  • 406
    Achievement of Clinical Isavuconazole (ISA) Serum and Plasma Drug Concentrations in Two Patients with Isavuconazonium Capsules Administered via Nasogastric Feeding Tube (NGT)
    Erin K. McCreary, PharmD, BCPS; Jared Borlagdan, PharmD; David R. Andes, M.D., FIDSA; Patrick Kinn, PharmD, MPH; Lucas T Schulz, PharmD, BCPS (AQ-ID); Alexander J. Lepak, M.D.
    407
    Changes in the utilization patterns of antifungal agents, medical cost and clinical outcomes of candidemia by health care benefit expansion to include newer antifungal agents
    Heun Choi, MD; Woonji Lee, MD; Hye Seong, MD; Jung Ho Kim, MD; Jin Young Ahn, MD; Su Jin Jeong, MD/PhD; Nam Su Ku, MD, PhD; Young Keun Kim, MD, PhD; Joon Sup Yeom, MD, PhD; Hyo Youl Kim, MD, PhD; Young Goo Song, MD, PhD; June Myung Kim, MD, PhD; Jun Yong Choi, MD, PhD
    409
    Changing Epidemiology of Fungal Bloodstream Infections in a Tertiary Care Center in India
    Vidya Menon, MD, FACP; Binny P P, MD; Fabia E T, MSc; Sanjeev Singh, DCH, MD, PhD; Keith S. Kaye, MD, MPH; Payal Patel, MD, MPH
    410
    Impact of Pediatric Antifungal Adverse Drug Reactions on Prescribing Practices
    Jennifer Goldman, MD, MS; Jason Newland, MD, MEd, FPIDS; Diana Yu, PharmD, BCPS-AQ ID; Karisma Patel, PharmD, BCPPS; Alaina Burns, PharmD; Ann Wirtz, PharmD; Brian R. Lee, MPH, PhD
    411
    Tolerability of Isavuconazole after Posaconazole Toxicity in Leukemia Patients
    Adam J. DiPippo, PharmD; Caitlin R. Rausch, PharmD; Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FACP, FIDSA, FECMM, FAAM
    412
    Clinical and Pharmacoeconomic Evaluation of Antifungal Prophylaxis with Continuous Micafungin compared to Posaconazole with Micafungin Bridging in Patients Undergoing Allogeneic Stem Cell Transplantation: A six-year Cohort-Analysis
    Sebastian M. Heimann, PhD; Maria J. G. T. Vehreschild, MD; Bernd Franke, Database development; Oliver Cornely, MD, FACP, FIDSA, FAAM; Axel Hamprecht, MD; Ellen Piepenbrock, MD; Christoph Scheid, MD; Janne Vehreschild, Prof. Dr. med.
    413
    Intravenous and Tablet Formulation of Posaconazole in Antifungal Therapy and Prophylaxis: A Retrospective, Non-Interventional, Multicenter Analysis of Patients Treated in German Tertiary-Care Hospitals
    Sebastian M. Heimann, PhD; Olaf Penack, Professor of Medicine; Werner J. Heinz, MD; Tobias Rachow, MD; Gerlinde Egerer, MD; Johanna Kessel, MD; Annika Löhnert, MD; Janne Vehreschild, Prof. Dr. med.
    414
    Diagnostic usefulness of differential time to positivity (DTP) in neutropenic cancer patients with suspected catheter-related candidemia (CRC)
    Kyeong Min Jo, M.D; Hae-In Kim, MD; Sungim Choi, M.D; Kyung Hwa Jung, MD; Jung Wan Park, MD; Ji Hyun Yun, M.D; Min Jae Kim, MD; Yong Pil Chong, MD, PhD; Sang-Oh Lee, MD, PhD; Sang-Ho Choi, MD, PhD; Yang Soo Kim, MD, PhD; Jun Hee Woo, MD; Jung-Hee Lee, MD, PhD; Je-Hwan Lee, MD, PhD; Kyoo-Hyung Lee, MD, PhD; Sung-Han Kim, MD, PhD
    415
    Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis
    Catherine DeVoe, MD; Monica Fung, MD, MPH; Brian Schwartz, MD; Sarah B. Doernberg, MD; Mimi Lo, PharmD; Larissa Graff, PharmD; Marisela Tan, PharmD; Aaron Logan, MD, PhD; Jennifer Babik, MD, PhD; Peter Chin-Hong, MD
    416
    Culture-documented invasive mold infections (cIMIs) at MD Anderson Cancer Center (MDACC) in Houston, TX pre and post hurricane Harvey
    Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FACP, FIDSA, FECMM, FAAM; Emily Shah, MPH, CIC; Linda Graviss, BS, CIC, MT; Issam Raad, MD; Roy Chemaly, MD, MPH
    419
    Diagnostic Performance of Immunohistochemistry Test to Differentiate Aspergillosis from Mucormycosis with Formalin-fixed tissue specimens
    Ji Hyun Yun, MD; Sungim Choi, M.D; Jung Wan Park, MD; Kyung Hwa Jung, MD; Kyeong Min Jo, M.D; Jiwon Jung, MD; Min Jae Kim, MD; Yong Pil Chong, MD, PhD; Sang-Oh Lee, MD, PhD; Sang-Ho Choi, MD, PhD; Jun Hee Woo, M.D; Yang Soo Kim, MD, PhD; Joon Seon Song, M.D; Young Soo Park, M.D; Sung-Han Kim, MD, PhD

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.